e-learning
resources
Paris 2018
Sunday, 16.09.2018
New pharmacological strategies in airway diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Late Breaking Abstract - CRAC channel inhibition by RP3128 triggers potent anti-inflammatory effects in COPD or asthmatic patient-derived primary cells
S. Viswanadha (La Chaux-de-Fonds, Switzerland), J. Cortijo (Valencia, Spain), J. Milara (Valencia, Spain), S. Vakkalanka (La Chaux-de-Fonds, Switzerland)
Source:
International Congress 2018 – New pharmacological strategies in airway diseases
Session:
New pharmacological strategies in airway diseases
Session type:
Oral Presentation
Number:
516
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Viswanadha (La Chaux-de-Fonds, Switzerland), J. Cortijo (Valencia, Spain), J. Milara (Valencia, Spain), S. Vakkalanka (La Chaux-de-Fonds, Switzerland). Late Breaking Abstract - CRAC channel inhibition by RP3128 triggers potent anti-inflammatory effects in COPD or asthmatic patient-derived primary cells. 516
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Late Breaking Abstract - Anti-inflammatory and anti-fibrotic effect of novel, pan-PDE inhibitors in human bronchial epithelial cells
Source: Virtual Congress 2020 – Scientific advances in airway pharmacology
Year: 2020
Inhibition of phosphodiesterase 4B enhances glucocorticoid-dependent gene transcription in human airway epithelial cells: Implications for the treatment of COPD
Source: Annual Congress 2013 –New drugs in respiratory medicine
Year: 2013
Tiotropium and olodaterol exert anti-proliferative effects on pulmonary fibroblasts of asthmatic patients in vitro
Source: Annual Congress 2013 –Airway smooth muscle and cell biology
Year: 2013
Late Breaking Abstract - Transcriptional response to RSV in asthma primary bronchial epithelial cells: are the basal cells responsible for the reduced NF-kB response?
Source: Virtual Congress 2021 – Mechanistic pathways in chronic and new lung diseases
Year: 2021
Inhibitors of apoptosis proteins in asthmatic airway inflammation
Source: Annual Congress 2013 –Asthma: new mechanisms and markers
Year: 2013
Late Breaking Abstract - Dose-dependent inactivation of airway tryptase with a novel dissociating anti-Tryptase antibody (MTPS9579A) in healthy volunteers
Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies
Year: 2019
Late Breaking Abstract - Hypoxia-induced cellular responses in lung fibroblasts from COPD patients and controls
Source: Virtual Congress 2021 – In vitro modelling of lung disease: reach out to the next dimension
Year: 2021
cPLA2alpha inhibitor ASB14780 suppresses airway MMP-9 production and improves respiratory function in cigarette-smoke induced model
Source: International Congress 2014 – Animal models in respiratory drug development
Year: 2014
TSPO a new anti-inflammatory target in the airway of COPD
Source: International Congress 2015 – Advances in the future treatment of COPD
Year: 2015
Alveolar macrophages activate STAT3 in epithelial cells via gp130 dependant steroid insensitive mechanism
Source: Annual Congress 2013 –Macrophages, mononuclear cells and viral infection
Year: 2013
Effect of mast cells degranulation blockade on the inflammatory response outcome in the COPD model
Source: International Congress 2016 – New signalling pathways in COPD
Year: 2016
RP6503, a novel and selective PI3K δ/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD
Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs
Year: 2014
Inhibitory effects of montelukast on mediator release by nasal epithelial cells from asthmatic subjects
Source: Annual Congress 2013 –The pulmonary epithelium: recent developments
Year: 2013
Effects of dexamethasone and anti-inflammatory drugs on inflammatory cytokines from bronchial epithelial cells of COPD patients
Source: International Congress 2015 – New insights into lung disease pathogenesis
Year: 2015
Nociceptin modulates the inflammatory immune microenvironment in a conventional murine model of asthma
Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis
Year: 2015
Extracellular ATP triggers and maintains airway inflammation in human and murine models of asthma by activating dendritic cells
Source: Annual Congress 2008 - New mechanisms in the pathogenesis of asthma and its response to treatment
Year: 2008
Dual mechanism of action of T2 inhibitor therapies in virally induced exacerbations of asthma: evidence for a beneficial counter-regulation
Source: Eur Respir J, 54 (1) 1802390; 10.1183/13993003.02390-2018
Year: 2019
Late Breaking Abstract - IL-36 receptor agonists contribute to a pro-inflammatory milieu in smokers with and without COPD
Source: International Congress 2017 – New immune markers for asthma and COPD
Year: 2017
An antedrug of the CXCL12 neutraligand blocks experimental allergic asthma without systemic effect in the mouse
Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD
Year: 2013
Anticholinergic treatment does not affect toll-like receptor 3-induced antiviral immune response in COPD bronchial epithelial cells
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept